Results 91 to 100 of about 7,633 (200)
Not Your Typical Ulcerative Colitis Patient [PDF]
Background: Extraintestinal manifestations (EIMs) of inflammatory bowel diseases (IBDs) are a common and debilitating feature of disease, occurring in up to 40% of patients with IBD.
Teodora SPATARU +3 more
doaj +1 more source
A rare case of mesalamine-induced eosinophilic pleural effusion
We present a very rare case of a 47-year-old man with a history of ulcerative colitis (UC), referred to as a case of an undiagnosed bilateral pleural effusion.
Ankit Bhatia +4 more
doaj +1 more source
Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX® mesalamine [PDF]
Ulcerative colitis (UC) is a chronic inflammatory disease of the colon that typically manifests as diarrhea, abdominal pain, and bloody stool. Complications, such as colorectal cancer and extraintestinal manifestations, may also develop.
Moss, Alan, Nanda, Kavinderjit
core +1 more source
Mesalamine intolerance in three children with Crohn’s disease
Objective: To present the mesalamine-induced acute exacerbation of symptoms and inflammatory markers in children with Crohn's disease (CD). Clinical Presentation and Intervention: Three children who presented with CD had acute exacerbation of colitis ...
Girgin, Nurten +9 more
core +1 more source
Background: Mesalamine is widely used for inflammatory bowel disease (IBD) due to its local anti-inflammatory action, while probiotics help restore intestinal microbiota and modulate immune responses. Combining both may offer synergistic benefits for IBD
Pratiksha A. Thete +2 more
doaj +1 more source
Simple one-pot green method for large-scale production of mesalamine, an anti-inflammatory agent
We report a rapid and efficient synthesis protocol for mesalamine via a green approach with 2-chloro-5-nitrobenzoic acid as the starting material, for its large-scale production.
Vijaya Lakshmi C. +2 more
doaj +1 more source
Acute pancreatitis associated with mesalamine: A case report and review of the literature
Mesalamine, widely used in the treatment of chronic inflammatory bowel disease, has been associated in some patients with the development of acute pancreatitis.
GALLERANI M. +11 more
core
Mesalamine-induced myopericarditis in children: a case report and a short revision of the literature [PDF]
Mesalamine has a central role in the treatment of inflammatory bowel disease (IBD). Myocarditis and/or pericarditis are rare and severe side effects of mesalamine-containing drugs.
Montanari F. +5 more
core +1 more source
Stability Enhancement of Mesalamine Delayed-Release Tablets 1.2g [PDF]
Mesalamine (5-aminosalicylic acid) is widely used for the treatment of inflammatory bowel disease (IBD), including ulcerative colitis. Commercially available mesalamine delayed-release formulations, such as LIALDA (Mesalamine) Delayed-Release Tablets 1.2
Anonymous,
core
Changes in T cell activation and soluble markers aggregating the 12 weeks on mesalamine.
Changes in T cell activation and soluble markers aggregating the 12 weeks on mesalamine.
Ma Somsouk (283498) +15 more
core +1 more source

